Australia markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
300.64+3.21 (+1.08%)
At close: 04:00PM EDT
300.64 0.00 (0.00%)
After hours: 07:01PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close297.43
Open299.85
Bid0.00 x 1100
Ask0.00 x 1000
Day's range295.87 - 303.00
52-week range176.36 - 305.95
Volume1,539,755
Avg. volume1,382,485
Market cap77.102B
Beta (5Y monthly)0.45
PE ratio (TTM)23.69
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

    BOSTON & ZUG, Switzerland, September 27, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that Vertex has concluded discussions with the U.S. Food and Drug Administration (FDA), and the FDA granted exagamglogene autotemcel (exa-cel) a rolling review for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Vertex will submit its biologics licensing application (BLA) for exa-cel for rol

  • Business Wire

    Vertex Appoints Jonathan Biller as Chief Legal Officer

    BOSTON, September 08, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer, effective September 19, 2022. Mr. Biller will report directly to Vertex’s Chief Executive Officer and President, Reshma Kewalramani, M.D., and join the company’s Executive Committee. In this role, Mr. Biller will oversee all of Vertex’s global legal and compliance functions.

  • Business Wire

    Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months

    BOSTON, September 02, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved expanded use of ORKAMBI® (lumacaftor/ivacaftor) to include children with cystic fibrosis (CF) ages 12 to <24 months who are homozygous for the F508del mutation (F/F genotype) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. ORKAMBI® was previously approved by the FDA for use in people with CF ages 2 years and older with two cop